Results 91 to 100 of about 42,609 (234)

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

Journal of Infectious Diseases, 2018
BACKGROUND Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2, is being developed for hospitalized and high-risk patients with influenza A.
R. Finberg, Riin Lanno, David Anderson, R. Fleischhackl, Wilbert van Duijnhoven, R. Kauffman, T. Kosoglou, J. Vingerhoets, L. Leopold   +8 more
semanticscholar   +1 more source

Evolution of H5N1 Cross‐Species Transmission: Adaptive Mutations Driving Avian‐to‐Human Infection

Advanced Genetics, Volume 7, Issue 1, March 2026.
This review synthesizes current knowledge on the molecular mechanisms underpinning H5N1's host adaptation, focusing on key mutations in viral proteins. Critical mutations are discussed in detail, highlighting their roles in altering receptor specificity, promoting antiviral resistance, and expanding viral tropism. The review underscores the urgent need
Wenxin Man, Lin Du, Ying Liu, Zehan Pang, Hongyan Zhu, Bixia Hong, Zhichao Xu, Huahao Fan   +7 more
wiley   +1 more source

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data

Health Technology Assessment, 2016
Background: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide.
Carl J Heneghan, Igho Onakpoya, Mark A Jones, Peter Doshi, Chris B Del Mar, Rokuro Hama, Matthew J Thompson, Elizabeth A Spencer, Kamal R Mahtani, David Nunan, Jeremy Howick, Tom Jefferson   +11 more
doaj   +1 more source

The Iowa Perinatal Letter, July-August-September 2009, Vol. 30, no. 3 [PDF]

, 2009
This newsletter from The Department of Public Health about perinatal health care and ...

core  

Frequency and Duration of the Clinical Symptoms of Patients With Mild COVID‐19: A Comparison With Influenza in the 2023–2024 Japanese Influenza Season, an Observational Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims This study aimed to compare the clinical symptoms of mild COVID‐19 and influenza during a period when both diseases circulated in the 2023–2024 influenza season in Japan. Methods Outpatients diagnosed with COVID‐19, influenza A, or influenza B by antigen test kits at 10 medical facilities in Japan were enrolled.
Takuma Bando, Hideyuki Ikematsu, Naoki Kawai, Tetsunari Maeda, Woon Joo Lee, Shinro Matsuura, Osame Tanaka, Takashi Kawashima, Hareaki Yamamoto, Ietaka Sato, Ken‐ichi Doniwa   +10 more
wiley   +1 more source

Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2020
Objective: To evaluate the effects of timely oseltamivir administration in patients hospitalized with seasonal influenza. Patients and Methods: We performed a single-center retrospective cohort study for hospitalized patients who tested positive for ...
Lin Dou, MD, Dan Reynolds, MD, Lindsey Wallace, MS, PA-C, John O’Horo, MD, MPH, Rahul Kashyap, MBBS, Ognjen Gajic, MD, Hemang Yadav, MBBS   +6 more
doaj   +1 more source

Functionalized selenium nanoparticles enhance the anti-EV71 activity of oseltamivir in human astrocytoma cell model

Artificial Cells Nanomedicine and Biotechnology, 2019
Enterovirus 71 (EV71) which commonly caused the hand-foot-mouth disease (HFMD) has become one of public health challenges worldwide. However, no effective vaccines or drugs for this disease has been developed.
Jia-yu Zhong, Yu Xia, L. Hua, Xiaomin Liu, M. Xiao, Tiantian Xu, B. Zhu, H. Cao   +7 more
semanticscholar   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.

PLoS ONE, 2019
BACKGROUND:Neuraminidase inhibitors (NAIs) effectively treat influenza. The clinical effectiveness of four NAIs (oseltamivir, zanamivir, laninamivir, and peramivir) was evaluated against influenza A/H1N1pdm09, A/H3N2, and B viruses.
Momoko Mawatari, Reiko Saito, Akinobu Hibino, Hiroki Kondo, Ren Yagami, Takashi Odagiri, Ikumi Tanabe, Yugo Shobugawa, Japanese Influenza Collaborative Study Group   +8 more
doaj   +1 more source

Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration

PLoS Pathogens, 2018
Severe influenza A virus infection causes high mortality and morbidity worldwide due to delayed antiviral treatment and inducing overwhelming immune responses, which contribute to immunopathological lung injury.
Xuehong Jia, Bo Liu, L. Bao, Qi Lv, Feng-di Li, Hui Li, Y. An, Xulong Zhang, B. Cao, Chen Wang   +9 more
semanticscholar   +1 more source